Kapitalforhøjelse i Lundbeck med 116.330 aktier (0,0585 % af udestående aktier) som følge af warrant-program for medarbejdere
November 21, 2017 05:28 ET
|
H. Lundbeck A/S
Valby, Danmark, 2017-11-21 11:28 CET (GLOBE NEWSWIRE) --
Valby, Danmark, 21. november 2017 - H. Lundbeck A/S (Lundbeck) har i dag offentliggjort beslutningen om at udvide aktiekapitalen med DKK...
Lundbeck increases its share capital by 116,330 shares (0.0585 % of outstanding shares) as a result of exercise of employee warrants
November 21, 2017 05:28 ET
|
H. Lundbeck A/S
Valby, Denmark, 2017-11-21 11:28 CET (GLOBE NEWSWIRE) --
Valby, Denmark, 21 November 2017 - H. Lundbeck A/S (Lundbeck) today announced that it has decided to increase its share capital by DKK...
Ledende medarbejderes og deres nærtståendes transaktioner med aktier og tilknyttede værdipapirer i H. Lundbeck A/S
November 17, 2017 12:55 ET
|
H. Lundbeck A/S
Valby, Danmark, 2017-11-17 18:55 CET (GLOBE NEWSWIRE) --
Valby, Danmark, 17. november 2017 - H. Lundbeck A/S (Lundbeck) skal herved offentliggøre og indberette ledende medarbejderes og disses...
Transactions with shares and linked securities in H. Lundbeck A/S made by executives and their closely associated parties
November 17, 2017 12:55 ET
|
H. Lundbeck A/S
Valby, Denmark, 2017-11-17 18:55 CET (GLOBE NEWSWIRE) --
Valby, Denmark, 17 November 2017 – H. Lundbeck A/S (Lundbeck) hereby publishes and reports transactions made by executives and persons...
Lundbeck increased operating profit (EBIT) with 126% and EPS by 182% in the first nine months of 2017
November 08, 2017 01:45 ET
|
H. Lundbeck A/S
Valby, Denmark, 2017-11-08 07:45 CET (GLOBE NEWSWIRE) --
HIGHLIGHTS
Revenue reached DKK 12,842 million in the first nine months of 2017 representing an increase of 12% (13% in local...
Lundbeck og Otsuka vil igangsætte et tredje fase III-studie til evaluering af effekten af brexpiprazol til behandling af agitationssymptomer hos patienter med demens af Alzheimer-typen
November 01, 2017 02:04 ET
|
H. Lundbeck A/S
Valby, Danmark, 2017-11-01 07:04 CET (GLOBE NEWSWIRE) --
Valby, Danmark og Tokyo, Japan, 1. november 2017 - H. Lundbeck A/S (Lundbeck) og Otsuka Pharmaceutical Co., Ltd. (Otsuka) annoncerer, at de...
Lundbeck and Otsuka will initiate a third phase III trial to evaluate the use of brexpiprazole in the treatment of agitation in patients with dementia of the Alzheimer's type
November 01, 2017 02:04 ET
|
H. Lundbeck A/S
Valby, Denmark, 2017-11-01 07:04 CET (GLOBE NEWSWIRE) --
Valby, Denmark and Tokyo, Japan, 1 November 2017 - H. Lundbeck A/S (Lundbeck) and Otsuka Pharmaceutical Co., Ltd. (Otsuka) announce that the...
Changes to Lundbeck’s Executive Management
October 30, 2017 15:48 ET
|
H. Lundbeck A/S
Valby, Denmark, 2017-10-30 20:48 CET (GLOBE NEWSWIRE) --
Valby, Denmark, 30 October 2017 - H. Lundbeck A/S (Lundbeck) today announced changes to its Executive Management team.
Following the...
Ændringer i Lundbecks koncernledelse
October 30, 2017 15:48 ET
|
H. Lundbeck A/S
Valby, Danmark, 2017-10-30 20:48 CET (GLOBE NEWSWIRE) --
Valby, Denmark, 30. oktober 2017 - H. Lundbeck A/S (Lundbeck) har i dag offentliggjort ændringer i selskabets koncernledelse (Executive...
Changes in Executive Management in Lundbeck
September 11, 2017 02:00 ET
|
H. Lundbeck A/S
Valby, Denmark, 2017-09-11 08:00 CEST (GLOBE NEWSWIRE) --
Kåre Schultz has resigned from his position as President and CEO to join Teva Pharmaceutical Industries Ltd. as President and...